Orelabrutinib

Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK) . (In Vitro) :With a proprietary formulation, Orelabrutinib (ICP-022) achieves high bioavailability comparing to other BTK inhibitors. (In Vivo) :Upon administration, Orelabrutinib (ICP-022) binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK.